In the CheckMate 040 trial (El-Khoueiry et al., 2017), nivolumab, a checkpoint inhibitor that blocks programmed cell death protein-1, demonstrated durable responses and prolonged long-term survival, which has been approved by FDA for second-line therapy of HCC. This evidence concerns the gene PDCD1 and hepatocellular carcinoma.